Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study

Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the precise consequences of targeting immune cell trafficking for immunoregulatory network functions are only incompletely...

詳細記述

保存先:
書誌詳細
出版年:Front Immunol
主要な著者: Lohmann, Lisa, Janoschka, Claudia, Schulte-Mecklenbeck, Andreas, Klinsing, Svenja, Kirstein, Lucienne, Hanning, Uta, Wirth, Timo, Schneider-Hohendorf, Tilman, Schwab, Nicholas, Gross, Catharina C., Eveslage, Maria, Meuth, Sven G., Wiendl, Heinz, Klotz, Luisa
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2018
主題:
Immunology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6052886/
https://ncbi.nlm.nih.gov/pubmed/30050529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01560
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料